GLP-1s and Menopause: A Double Opportunity to Protect Your Heart

Heart risk rises during menopause because the loss of estrogen removes several forms of cardiovascular protection at once. Before menopause, estrogen helps keep blood vessels flexible, supports a favorable cholesterol profile, and helps regulate blood pressure — which is why premenopausal women have lower rates of heart disease than men their age. As estrogen falls, arteries stiffen, LDL ('bad') cholesterol and triglycerides tend to rise, HDL becomes less protective, blood pressure creeps up, and fat redistributes toward the abdomen as metabolically active visceral fat.

The American Heart Association has formally recognized the menopause transition as a time of accelerating cardiovascular risk, drawing heavily on data from the Study of Women's Health Across the Nation (SWAN). SWAN documented that the years around the final menstrual period bring unfavorable changes in cholesterol, arterial stiffness, and body composition that are not explained by aging alone. In other words, menopause itself — not just getting older — nudges the cardiovascular system in the wrong direction. This is why midlife is increasingly framed as a critical window to measure and manage heart-health markers. Our guides on [menopause and heart disease risk](/blog/menopause-heart-disease-risk-what-swan-study-found) and [why blood pressure rises in menopause](/blog/menopause-and-blood-pressure-why-it-rises-and-what-helps) cover this shift in detail.

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), published in the *New England Journal of Medicine* in 2023, was the landmark study showing a GLP-1 protects the heart in people without diabetes. It enrolled more than 17,000 adults aged 45 and older who had overweight or obesity plus established cardiovascular disease, and followed them for several years. The result: semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events — cardiovascular death, heart attack, or stroke — by 20% compared with placebo (6.5% vs 8.0% of participants; hazard ratio 0.80).

What makes SELECT so important is that the benefit appeared larger and earlier than weight loss alone would explain, suggesting GLP-1s also act on inflammation, blood vessel function, and blood pressure directly. This reframed GLP-1s from purely weight-loss or diabetes drugs into medications with proven cardiovascular value. For a deeper dive, see our [full breakdown of the SELECT trial](/blog/glp1-heart-health-select-trial-cardiovascular-benefits). The trial population skewed older, which means a substantial share of the women enrolled were postmenopausal — exactly the group facing rising heart risk from the menopause transition.

The overlap is striking: GLP-1s tend to lower exactly the risk factors menopause raises. Menopause increases visceral fat; GLP-1s preferentially reduce it. Menopause pushes blood pressure up; semaglutide modestly lowers systolic blood pressure. Menopause worsens the cholesterol and triglyceride profile; GLP-1s improve several of these markers. Menopause is associated with rising inflammation and insulin resistance; GLP-1s improve both. For a woman in her late 40s or 50s, starting a GLP-1 can therefore push back against several menopause-driven cardiovascular changes simultaneously.

This does not make a GLP-1 a menopause treatment or a replacement for blood-pressure or cholesterol medication when those are needed — and it is not a substitute for hormone therapy, which addresses symptoms and has its own cardiovascular considerations depending on timing and route. Rather, it means that for midlife women who qualify, the cardiometabolic timing is favorable. Some women use a GLP-1 and HRT together under medical supervision; our guide on [combining HRT and GLP-1](/blog/hrt-and-glp1-together-menopause-weight-loss-synergy) explains what is known. And because visceral belly fat is such a central player in both menopause and heart risk, our [GLP-1 and visceral fat in menopause guide](/blog/glp1-and-visceral-fat-in-menopause-targeting-belly-fat) is worth reading alongside this one.

The biggest cautions are protecting muscle and bone, which are already vulnerable in menopause. Rapid weight loss on any method can cost lean muscle, and menopause accelerates both muscle loss (sarcopenia) and bone loss as estrogen falls. That combination is why resistance training and adequate protein are not optional on a GLP-1 in midlife — they are the safeguard that keeps weight loss from weakening you. Aim for protein at every meal and strength work two to three times a week; our [muscle preservation guide](/blog/muscle-preservation-on-glp1-strength-training-protein-guide) has the specifics.

Also keep the routine GLP-1 considerations in view: manage GI side effects, stay hydrated (menopause and GLP-1s both affect fluid balance), and keep up with cardiovascular monitoring — blood pressure, cholesterol, and blood sugar — rather than assuming the medication covers everything. A GLP-1 is a powerful tool, but heart protection in menopause is a *portfolio*: medication where appropriate, plus movement, diet, sleep, not smoking, and treating hypertension or high cholesterol directly. Work with a clinician who understands both menopause and cardiometabolic medicine so your plan fits the whole picture. Used thoughtfully, this can be one of the most productive health windows of midlife — a chance to reset trajectory rather than just chase symptoms.